Cargando…

Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study

OBJECTIVE: To report the efficacy, long-term safety, and tolerability of using a small dose (125 mg/m2 weekly for 4 weeks) of rituximab to treat Chinese patients with thyroid-associated ophthalmopathy (TAO). METHODS: Seven patients with active moderate-to-severe TAO were prospectively recruited in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yueyue, Hu, Hao, Chen, Lu, Zhang, Haitao, Yang, Tao, Xu, Xiaoquan, Chen, Huanhuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889535/
https://www.ncbi.nlm.nih.gov/pubmed/36743915
http://dx.doi.org/10.3389/fendo.2022.1079852
_version_ 1784880753512808448
author Wang, Yueyue
Hu, Hao
Chen, Lu
Zhang, Haitao
Yang, Tao
Xu, Xiaoquan
Chen, Huanhuan
author_facet Wang, Yueyue
Hu, Hao
Chen, Lu
Zhang, Haitao
Yang, Tao
Xu, Xiaoquan
Chen, Huanhuan
author_sort Wang, Yueyue
collection PubMed
description OBJECTIVE: To report the efficacy, long-term safety, and tolerability of using a small dose (125 mg/m2 weekly for 4 weeks) of rituximab to treat Chinese patients with thyroid-associated ophthalmopathy (TAO). METHODS: Seven patients with active moderate-to-severe TAO were prospectively recruited in this study. A small dose of rituximab (125mg/m2 body surface area) was given weekly with a duration of four weeks. Thyroid function, thyrotropin receptor antibody (TRAb), B cell and T cell subsets, ophthalmological examination, magnetic resonance imaging derived parameters, and adverse reactions were recorded at each visit. RESULTS: Seven patients were followed for an average of 224 weeks. B-cell depletion was observed in all patients following rituximab infusion. The clinical activity score (CAS) decreased from 4.86 ± 0.69 to 3.00 ± 0.82 at 5 weeks after treatment (P = 0.033) and remained significantly lower than baseline values at the end of follow-up (P = 0.001). Compared to baseline values, significant decreases in exophthalmos of the right eye, the thickness of extraocular muscles with maximum signal intensity, and the highest signal intensity ratio (SIR) of extraocular muscle to ipsilateral temporal muscle values were observed at the last follow-up (all P < 0.05). Disease progressions or recurrences were not observed during follow-up. Only mild fatigue was observed after the first infusion as a side effect (n = 1). CONCLUSION: Small dose of rituximab may be a promising option with adequate safety, tolerability, and long-term efficacy for patients with active moderate-to-severe TAO.
format Online
Article
Text
id pubmed-9889535
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98895352023-02-02 Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study Wang, Yueyue Hu, Hao Chen, Lu Zhang, Haitao Yang, Tao Xu, Xiaoquan Chen, Huanhuan Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: To report the efficacy, long-term safety, and tolerability of using a small dose (125 mg/m2 weekly for 4 weeks) of rituximab to treat Chinese patients with thyroid-associated ophthalmopathy (TAO). METHODS: Seven patients with active moderate-to-severe TAO were prospectively recruited in this study. A small dose of rituximab (125mg/m2 body surface area) was given weekly with a duration of four weeks. Thyroid function, thyrotropin receptor antibody (TRAb), B cell and T cell subsets, ophthalmological examination, magnetic resonance imaging derived parameters, and adverse reactions were recorded at each visit. RESULTS: Seven patients were followed for an average of 224 weeks. B-cell depletion was observed in all patients following rituximab infusion. The clinical activity score (CAS) decreased from 4.86 ± 0.69 to 3.00 ± 0.82 at 5 weeks after treatment (P = 0.033) and remained significantly lower than baseline values at the end of follow-up (P = 0.001). Compared to baseline values, significant decreases in exophthalmos of the right eye, the thickness of extraocular muscles with maximum signal intensity, and the highest signal intensity ratio (SIR) of extraocular muscle to ipsilateral temporal muscle values were observed at the last follow-up (all P < 0.05). Disease progressions or recurrences were not observed during follow-up. Only mild fatigue was observed after the first infusion as a side effect (n = 1). CONCLUSION: Small dose of rituximab may be a promising option with adequate safety, tolerability, and long-term efficacy for patients with active moderate-to-severe TAO. Frontiers Media S.A. 2023-01-18 /pmc/articles/PMC9889535/ /pubmed/36743915 http://dx.doi.org/10.3389/fendo.2022.1079852 Text en Copyright © 2023 Wang, Hu, Chen, Zhang, Yang, Xu and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wang, Yueyue
Hu, Hao
Chen, Lu
Zhang, Haitao
Yang, Tao
Xu, Xiaoquan
Chen, Huanhuan
Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study
title Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study
title_full Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study
title_fullStr Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study
title_full_unstemmed Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study
title_short Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study
title_sort observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven chinese patients: one pilot study
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889535/
https://www.ncbi.nlm.nih.gov/pubmed/36743915
http://dx.doi.org/10.3389/fendo.2022.1079852
work_keys_str_mv AT wangyueyue observationstudyofusingasmalldoseofrituximabtreatmentforthyroidassociatedophthalmopathyinsevenchinesepatientsonepilotstudy
AT huhao observationstudyofusingasmalldoseofrituximabtreatmentforthyroidassociatedophthalmopathyinsevenchinesepatientsonepilotstudy
AT chenlu observationstudyofusingasmalldoseofrituximabtreatmentforthyroidassociatedophthalmopathyinsevenchinesepatientsonepilotstudy
AT zhanghaitao observationstudyofusingasmalldoseofrituximabtreatmentforthyroidassociatedophthalmopathyinsevenchinesepatientsonepilotstudy
AT yangtao observationstudyofusingasmalldoseofrituximabtreatmentforthyroidassociatedophthalmopathyinsevenchinesepatientsonepilotstudy
AT xuxiaoquan observationstudyofusingasmalldoseofrituximabtreatmentforthyroidassociatedophthalmopathyinsevenchinesepatientsonepilotstudy
AT chenhuanhuan observationstudyofusingasmalldoseofrituximabtreatmentforthyroidassociatedophthalmopathyinsevenchinesepatientsonepilotstudy